Astrazeneca plc ADR (NASDAQ: AZN) kicked off on Tuesday, down -0.06% from the previous trading day, before settling in for the closing price of $66.40. Over the past 52 weeks, AZN has traded in a range of $60.47-$87.68.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 16.24%. While this was happening, its average annual earnings per share was recorded 13.72%. With a float of $3.10 billion, this company’s outstanding shares have now reached $3.10 billion.
Let’s determine the extent of company efficiency that accounts for 89900 employees. In terms of profitability, gross margin is 77.2%, operating margin of 18.41%, and the pretax margin is 15.5%.
Astrazeneca plc ADR (AZN) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of Astrazeneca plc ADR is 0.03%, while institutional ownership is 15.79%.
Astrazeneca plc ADR (AZN) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported 0.73 earnings per share (EPS), lower than consensus estimate (set at 0.76) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to 17.72% growth over the previous five years of trading.
Astrazeneca plc ADR (NASDAQ: AZN) Trading Performance Indicators
Take a look at Astrazeneca plc ADR’s (AZN) current performance indicators. Last quarter, stock had a quick ratio of 0.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.02. Likewise, its price to free cash flow for the trailing twelve months is 20.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.08, a number that is poised to hit 1.06 in the next quarter and is forecasted to reach 4.73 in one year’s time.
Technical Analysis of Astrazeneca plc ADR (AZN)
Looking closely at Astrazeneca plc ADR (NASDAQ: AZN), its last 5-days average volume was 6.76 million, which is a jump from its year-to-date volume of 5.33 million. As of the previous 9 days, the stock’s Stochastic %D was 87.33%. Additionally, its Average True Range was 1.43.
During the past 100 days, Astrazeneca plc ADR’s (AZN) raw stochastic average was set at 14.48%, which indicates a significant decrease from 88.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 18.62% in the past 14 days, which was lower than the 22.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $72.95, while its 200-day Moving Average is $74.75. However, in the short run, Astrazeneca plc ADR’s stock first resistance to watch stands at $66.83. Second resistance stands at $67.29. The third major resistance level sits at $67.77. If the price goes on to break the first support level at $65.89, it is likely to go to the next support level at $65.41. Should the price break the second support level, the third support level stands at $64.95.
Astrazeneca plc ADR (NASDAQ: AZN) Key Stats
The company with the Market Capitalisation of 205.76 billion has total of 3,100,608K Shares Outstanding. Its annual sales at the moment are 45,811 M in contrast with the sum of 5,955 M annual income. Company’s last quarter sales were recorded 13,565 M and last quarter income was 1,429 M.
